JNJ:TSX, Johnson & Johnson CDR (CAD Hedged)
JNJ stock overview
Johnson & Johnson CDR (CAD Hedged) (JNJ:TSX) closed at $33.64 on October 23, 2026,
down 1.38% on the day.
The stock trades 6.5% below its 52-week high of $35.96
and 28.5% above its 52-week low of $26.17.
Over the past year, it gained 26.0%.
Johnson & Johnson CDR (CAD Hedged) is part of the Health Care sector.
Key figures
- Price
- $33.64
- Day change
- -1.38%
- Volume
- 10,401
- Average volume
- 16,148
- Market cap
- 833B+
- 52-week range
- $26.17 – $35.96
- 50-day average
- $33.87
- 200-day average
- $31.48
Price action over the past year
In 209 trading sessions since December 23, 2025, JNJ closed higher on 108 days (52%).
Its best day was October 22, 2026 (+3.80%) and its worst was October 13, 2026 (-4.74%).
It never moved 10% or more in a single session.
Recent signals
JNJ news
-
Oct 25, 2026:
T-Bills Yield Up to 4.45%. Why Would Retirees Choose Dividend Stocks?
-
Oct 25, 2026:
Smith & Nephew (LSE:SN.) Stays Independent, Is It 8% Undervalued?
-
Oct 25, 2026:
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
-
Oct 25, 2026:
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
-
Oct 24, 2026:
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?
-
Oct 24, 2026:
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
-
Oct 24, 2026:
J&J's Smith & Nephew Deal Collapsed Over One Executive. Here's What It Means for the DePuy Spin
-
Oct 24, 2026:
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
About Johnson & Johnson CDR (CAD Hedged)
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Similar stocks
Find more stocks like JNJ with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.